• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study.

作者信息

Van Voorhees A S, Stein Gold L, Lebwohl M, Strober B, Sofen H, Papp K, Bagel J, Zhang Z, Paris M, Wang Y

机构信息

Eastern Virginia Medical School, Norfolk, VA, USA.

Henry Ford Health System, West Bloomfield, MI, USA.

出版信息

Br J Dermatol. 2021 Oct;185(4):840-842. doi: 10.1111/bjd.20083. Epub 2021 Jul 14.

DOI:10.1111/bjd.20083
PMID:33763874
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8518877/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27d7/8518877/6de54d7c65cc/BJD-185-840-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27d7/8518877/6de54d7c65cc/BJD-185-840-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27d7/8518877/6de54d7c65cc/BJD-185-840-g001.jpg

相似文献

1
Efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study.阿普米拉斯治疗中重度头皮斑块状银屑病患者的疗效和安全性：一项随机III期研究长达32周的结果
Br J Dermatol. 2021 Oct;185(4):840-842. doi: 10.1111/bjd.20083. Epub 2021 Jul 14.
2
Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study.阿普米司特治疗中重度头皮斑块状银屑病的疗效和安全性：一项 3b 期、多中心、随机、安慰剂对照、双盲研究的结果。
J Am Acad Dermatol. 2020 Jul;83(1):96-103. doi: 10.1016/j.jaad.2020.01.072. Epub 2020 Feb 4.
3
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).阿普米司特，一种口服磷酸二酯酶 4 抑制剂，用于治疗难治性指甲和头皮银屑病患者：两项 III 期随机对照试验（ESTEEM 1 和 ESTEEM 2）的结果。
J Am Acad Dermatol. 2016 Jan;74(1):134-42. doi: 10.1016/j.jaad.2015.09.001.
4
Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.在 LIBERATE 研究中，接受阿普司特治疗或从依那西普治疗转换的中重度斑块状银屑病患者中，阿普司特治疗 104 周的安全性和疗效。
J Eur Acad Dermatol Venereol. 2018 Mar;32(3):397-402. doi: 10.1111/jdv.14738. Epub 2018 Jan 29.
5
Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial.阿普米拉斯治疗轻至中度斑块状银屑病患者的疗效和安全性：一项3期、多中心、随机、双盲、安慰剂对照试验的结果。
J Am Acad Dermatol. 2022 Jan;86(1):77-85. doi: 10.1016/j.jaad.2021.07.040. Epub 2021 Jul 31.
6
Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study.阿普米司特治疗中重度斑块状银屑病的疗效和安全性：一项 II 期、多中心、随机、双盲、安慰剂对照、平行分组、剂量比较研究的结果。
J Eur Acad Dermatol Venereol. 2013 Mar;27(3):e376-83. doi: 10.1111/j.1468-3083.2012.04716.x. Epub 2012 Oct 3.
7
The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).阿普米拉斯、依那西普和安慰剂治疗中重度斑块状银屑病患者的疗效和安全性：一项IIIb期随机安慰剂对照试验（LIBERATE）的52周结果
J Eur Acad Dermatol Venereol. 2017 Mar;31(3):507-517. doi: 10.1111/jdv.14015. Epub 2016 Dec 19.
8
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).阿普米司特，一种口服磷酸二酯酶 4 抑制剂，治疗中重度斑块状银屑病患者的疗效和安全性：一项为期 52 周的 III 期随机对照试验（ESTEEM 2）。
Br J Dermatol. 2015 Dec;173(6):1387-99. doi: 10.1111/bjd.14164. Epub 2015 Nov 7.
9
Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.阿普司特在中度斑块状银屑病初治患者中的疗效和安全性：UNVEIL研究的52周结果
J Drugs Dermatol. 2018 Feb 1;17(2):221-228.
10
Apremilast for the management of moderate to severe plaque psoriasis.阿普米拉斯用于治疗中度至重度斑块状银屑病。
Expert Rev Clin Pharmacol. 2017 Apr;10(4):349-360. doi: 10.1080/17512433.2017.1293519. Epub 2017 Feb 17.

本文引用的文献

1
Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study.阿普米司特治疗中重度头皮斑块状银屑病的疗效和安全性：一项 3b 期、多中心、随机、安慰剂对照、双盲研究的结果。
J Am Acad Dermatol. 2020 Jul;83(1):96-103. doi: 10.1016/j.jaad.2020.01.072. Epub 2020 Feb 4.
2
Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents.银屑病：哪种疗法适合哪种患者：银屑病合并症和首选的系统药物。
J Am Acad Dermatol. 2019 Jan;80(1):27-40. doi: 10.1016/j.jaad.2018.06.057. Epub 2018 Jul 11.
3
Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
古塞单抗治疗特定身体区域银屑病的疗效与阿达木单抗和安慰剂的比较：两项随机临床试验的二次分析。
JAMA Dermatol. 2018 Jun 1;154(6):676-683. doi: 10.1001/jamadermatol.2018.0793.
4
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).银屑病患者阿普米司特的长期安全性和耐受性：来自 2 项 3 期、随机、对照试验（ESTEEM1 和 2）≥156 周的汇总安全性分析。
J Am Acad Dermatol. 2017 Aug;77(2):310-317.e1. doi: 10.1016/j.jaad.2017.01.052. Epub 2017 Apr 14.
5
Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3).使用司库奇尤单抗治疗中度至重度头皮受累银屑病的持续缓解：三项3期试验（UNCOVER-1、UNCOVER-2、UNCOVER-3）的结果
J Dermatolog Treat. 2017 Jun;28(4):282-287. doi: 10.1080/09546634.2016.1249820. Epub 2016 Nov 13.
6
Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data.确定皮肤病生活质量指数（DLQI）的最小临床重要差异和反应性：更多数据
Dermatology. 2015;230(1):27-33. doi: 10.1159/000365390. Epub 2015 Jan 20.
7
Clinical characteristics of pruritus in patients with scalp psoriasis and their relation with intraepidermal nerve fiber density.头皮银屑病患者瘙痒的临床特征及其与表皮内神经纤维密度的关系。
Ann Dermatol. 2014 Dec;26(6):727-32. doi: 10.5021/ad.2014.26.6.727. Epub 2014 Nov 26.
8
Scalp psoriasis, clinical presentations and therapeutic management.头皮银屑病：临床表现与治疗管理
Dermatology. 1998;197(4):326-34. doi: 10.1159/000018026.